Navigation Links
Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging,Growth Opportunities Conference

BLOOMFIELD, N.J., July 05, 2007 /PRNewswire/ -- Alfacell Corporation today announced that Lawrence A. Kenyon, executive vice president, chief financial officer and corporate secretary, will present an overview of the company's product development programs at 8 a.m. EDT on Thursday, July 12, 2007, at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference in New York.

The audio and slide presentation will be available live at http://www.wsw.com/webcast/ceut6/acel.ob/. A replay will be available at this address within 24 hours of the presentation and will be archived for 90 days.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE(R), is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. In addition to an ongoing Phase IIIb study in malignant mesothelioma, Alfacell is conducting a Phase I/II trial of ONCONASE in non-small cell lung cancer (NSCLC) and other solid tumors. For more information, visit www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, uncertainties involved in transitioning from concept to product, uncertainties involving the ability of the company to finance research and development activities, potential challenges to or violations of patents, uncertainties regarding the outcome of clinical trials, the company's ability to secure necessary approvals from regulatory agencies, dependence upon third-party vendors, and other risks discussed in the company's periodic filings with the Securities and Exchange Commission. By making these forward-looking statements, the company undertakes no obligation to update these statements for revisions or changes after the date of this release.

    Media Contact:                      Investor Contact:

    David Schull or Wendy Lau           Andreas Marathovouniotis

    Russo Partners                      Russo Partners

    212-845-4271                        212-845-4253

       

    

david.schull@russopartnersllc.com andreas.marathis@russopartnersllc.com wendy.lau@russopartnersllc.com

CONTACT: Media: David Schull, , or WendyLau, , +1-212-845-4271, or Investors: AndreasMarathovouniotis, , +1-212-845- 4253,all of Russo Partners for Alfacell Corporation david.schull@russopartnersllc.com wendy.lau@russopartnersllc.com andreas.marathis@russopartnersllc.com

Web site: http://www.alfacell.com/

Ticker Symbol: (NASDAQ-NMS:ACEL)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. In Vitro and In Vivo Data Show Alfacells Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells
2. Preclinical Data Show Alfacells Onconase Inhibits Tumor Growth of Non-Small Cell Lung Cancer, Breast Cancer Cells
3. Researchers Identify Intracellular Pathway of Alfacells Onconase
4. In vivo Study Results Demonstrating Potential of Alfacells Onconase for Treatment of Non-Small Cell Lung Cancer Published in Anticancer Research
5. Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacells Onconase
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
8. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
9. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
10. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
11. The Past, Present and Future of HLA Typing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... quarter ended June 30, 2017, and updated its financial ... For the fiscal third quarter, Hill-Rom reported ... per diluted share in the prior-year period. These results ... per diluted share primarily related to the non-cash write-down ...
(Date:7/27/2017)... Pharmaceutical Services, Inc. (NYSE: WST ) today ... updated financial guidance for the full-year 2017. ... Reported net sales of $397.6 million, a record ... at constant currency (organic) grew by 3.9%. ... $0.60 in the prior-year quarter. Second-quarter 2017 adjusted diluted ...
(Date:7/26/2017)... July 26, 2017 Sancilio Pharmaceuticals Company, Inc. ... clinical trial evaluating Altemia TM , an oral therapy ... Sickle Cell Disease (SCD). The SCOT Trial, is a ... and safety of Altemia TM in pediatric patients ... US IND 125274. ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... An August 2 article ... obtaining plastic surgery, largely influenced by the growing popularity of “pretty boys” in both ... notes that standards of male appearance are changing not only in the Asian nation, ...
(Date:8/17/2017)... ... 2017 , ... Pot Valet is a leading provider of premium medical-grade cannabis ... state, and soon, every state in the country, the company offers patients safe, legal, ... altogether. , According to Pot Valet, all California patients have the legal ...
(Date:8/17/2017)... (PRWEB) , ... August 17, 2017 , ... A recent ... to the biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines ... Part 11 ruling. , Presented as part of the Beckman Coulter Life ...
(Date:8/16/2017)... Los Angeles, California (PRWEB) , ... August 16, 2017 , ... An August 3rd ... patients that was the subject of a report in JAMA (the Journal of the American ... (BMIs) above 50 were able to achieve BMIs under 30, when compared to patients with ...
(Date:8/16/2017)... ... August 16, 2017 , ... For the second ... England student to educate the public on the impact of concussions. Brooke Mills, ... first-ever National Concussion Awareness Day. , Brooke is working diligently is to raise ...
Breaking Medicine News(10 mins):